Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.
Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.
复制标题
通过过继化学免疫疗法治愈患有晚期、高度转移、耐药肿瘤的小鼠。
DOI：
10.1007/bf01740904
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Dray,S
中科院分区：
文献类型：
--
作者：
Laude,M;Russo,KL;Mokyr,MB;Dray,S
我们在此表明，与携带晚期大型MOPC-315浆细胞瘤的BALB/c小鼠相反，携带晚期大型RPC-5浆细胞瘤的BALB/c小鼠不能通过环磷酰胺治疗（15、50、100或200 mg/kg）治愈。然而，大多数携带晚期RPC-5肿瘤的BALB/c小鼠通过环磷酰胺治疗（100 mg/kg）联合过继免疫治疗治愈，过继免疫治疗使用的是与灭活的RPC-5肿瘤细胞加聚乙二醇6000一起培养的肿瘤浸润脾细胞（TISpC），即使该方案对携带几乎不可触及的早期RPC-5肿瘤的小鼠的治疗无效。只有少数在过继性化学免疫治疗（ACIT）后治愈晚期RPC-5肿瘤的小鼠对随后的RPC-5肿瘤细胞攻击具有抗性。然而，当肿瘤变大时，已经发展出逐渐生长的肿瘤的受攻击小鼠可以通过单独的环磷酰胺治愈，即使这种治疗对于携带类似大小的肿瘤但先前未接受ACIT治疗的小鼠没有治愈性。因此，通过ACIT治愈具有广泛转移的致死性晚期RPC-5肿瘤的BALB/c小鼠提供了一种新的实验肿瘤模型，用于研究化疗药物和过继性细胞免疫疗法可以合作导致大肿瘤负荷完全消退的机制。
We show here that in contrast to BALB/c mice bearing a late-stage, large MOPC-315 plasmacytoma, BALB/c mice bearing a late-stage, large RPC-5 plasmacytoma were not cured by cyclophosphamide therapy (15, 50, 100 or 200 mg/kg). However, most BALB/c mice bearing a late-stage RPC-5 tumor were cured by cyclophosphamide therapy (100 mg/kg) in conjunction with adoptive immunotherapy using tumor-infiltrated spleen cells (TISpC) that had been cultured with inactivated RPC-5 tumor cells plus polyethylene glycol 6000, even though this protocol was not effective for the therapy of mice bearing a barely palpable, early-stage RPC-5 tumor. Only a few of the mice that were cured of a late-stage RPC-5 tumor following adoptive chemoimmunotherapy (ACIT) were resistant to a subsequent challenge with RPC-5 tumor cells. However, the challenged mice that had developed progressively growing tumors could then be cured by cyclophosphamide alone when the tumor became large, even though this treatment was not curative for mice bearing a tumor of similar size but not previously treated by ACIT. Thus, the cure by ACIT of BALB/c mice bearing a lethal, late-stage RPC-5 tumor with extensive metastases provides a novel experimental tumor model for investigating the mechanisms by which a chemotherapeutic drug and adoptive cellular immunotherapy can cooperate in causing the complete regression of a large tumor load.
登录
查看更多内容
超强 α-促黑激素刺激 S91 黑色素瘤酪氨酸酶活性。
影响因子：
4.1
作者：
Marwan,MM;AbdelMalek,ZA;Kreutzfeld,KL;Hadley,ME;Wilkes,BC;Hruby,VJ;Castrucci,AM
通讯作者：
Castrucci,AM
前列腺素 E 在体内和体外抑制肿瘤生长
影响因子：
64.8
作者：
M. Santoro;Gordon W. Philpott;Bernard M. Jaffe
通讯作者：
Bernard M. Jaffe
影响因子：
11.2
作者：
M. D. Bregman;C. Funk;M. Fukushima
通讯作者：
M. D. Bregman;C. Funk;M. Fukushima
小鼠黑色素瘤在无血清培养基中的锚定非依赖性生长依赖于胰岛素或黑素细胞刺激激素。
影响因子：
3.7
作者：
Bregman,MD;AbdelMalek,ZA;MeyskensJr,FL
通讯作者：
MeyskensJr,FL
影响因子：
56.9
作者：
POMERANTZ, SH
通讯作者：
POMERANTZ, SH